A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study
详细信息 查看全文
- 作者：Enrico Montanaria ; emontanari@ausl.pr.it" class="auth_mail" title="E-mail the corresponding author ; Mariarosa Rottolib ; Davide Maimonec ; Paolo Confalonierid ; Katrin Plewniae ; Maura Frigof ; Ada Franciag ; Antonello Palah ; Nunzia Alessandra Losignorei ; Paolo Ragonesej ; Antonella Venezianok ; on behalf of the POSIDONIA study group
- 关键词：Multiple sclerosis ; Disease-modifying treatment ; Emotional burden ; Anxiety ; Depression
- 刊名：Journal of the Neurological Sciences
- 出版年：2016
- 出版时间：15 May 2016
- 年：2016
- 卷：364
- 期：Complete
- 页码：105-109
- 全文大小：211 K
文摘
- •
Mean baseline HADS total, HADS-A and HADS-D subscale scores were within normal.
- •
Mean HADS total, HADS-A or HADS-D subscale scores did not change with time (p > 0.05).
- •
Patients with baseline HADS scores indicating anxiety/depression tended to improve.
- •
HDRS and IES-R total scores improved over time (p < 0.05).
- •
Disease-modifying treatment may improve emotional burden in patients with MS.